The press release and the live webcast can be accessed by visiting the Investors section of the Company's website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE® (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.
Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.
Contact: Kyle Kuvalanka Theresa McNeely Investor Relations Media Relations (617) 761-4734 (617) 761-6996
Source: Millennium Pharmaceuticals, Inc.
